Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELX-02 in healthy adult volunteers
NCT03292302Phase 1Completed
- Start
- Sep 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) and nephropathic cystinosis comparing Placebo Arm with ELX-02 Arm (2 arms). Primary endpoints: Adverse Events, Maximum plasma concentration and 8 more. Started Sep 2017; status: completed.
02
Drugs
exaluren
03
Conditions
cystic fibrosis (CF)nephropathic cystinosis
Beyond the preview
Go deeper on NCT03292302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292302.